Drug Trial Radar · NCT04036682
A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
284
Planned (sponsor's estimate)
Start
Oct 31, 2019
Primary completion
Oct 13, 2025
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Cullinan Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Taiho Oncology, Inc.
- First posted
- Jul 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
CLN-081-001 is a Phase 1/2, open label, multi-center study of CLN-081 in patients with non-small cell lung cancer (NSCLC) harboring EGFR (epidermal growth factor receptor) exon 20 insertion mutations, to characterize the safety, determine the recommended Phase 2 dose (RP2D), and evaluate efficacy.
Conditions
- Non Small Cell Lung Cancer
- EGFR Exon 20 Mutation
Interventions
CLN-081Drug
CLN-081 tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- All Cohorts: The rate and severity of treatment emergent AEs.Time frame: 24 months
- All Cohorts: The rate and severity of DLTs.Time frame: 24 months
- Phase 2 Dose Expansion Cohorts: Overall response rate (ORR)Time frame: 24 months
- Module A: Pharmacokinetic (PK) parameterTime frame: 24 months
- Module A: Pharmacokinetic (PK) parameterTime frame: 24 months
- Module B and C: Confirmed overall response rate (ORR) and duration of response (DOR) by independent review committee (IRC)Time frame: 24 months
Locations
64 sites in 9 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center, Inc
Anaheim, California
City of Hope Comprehensive Cancer Center
Duarte, California
City of Hope at Irvine Lennar
Irvine, California
Pacific Shores Medical Group
Long Beach, California
AdventHealth
Orlando, Florida
Massachusetts General Hospital
Boston, Massachusetts
University of Michigan Health System - University Hospital
Ann Arbor, Michigan
Summit Medical Group PA
Florham Park, New Jersey
Perlmutter Cancer Center at NYU Langone Hospital - Long Island
Mineola, New York
New York University Langone Health
New York, New York
Columbia University Irving Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Gabrail Cancer Center Research
Canton, Ohio
Providence Cancer Center
Portland, Oregon
Providence Oncology & Hematology Care Clinic-Westside
Portland, Oregon
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Virginia Cancer Specialists
Fairfax, Virginia
Hong Kong University - Queen Mary Hospital
Hong Kong, Hong Kong
Azienda Ospedaliero Universitaria Careggi
Careggi, Italy
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I
Marche, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS
Meldola, Italy
IRCCS-Istituto Europeo di Oncologia
Milan, Italy
Azienda Ospedaliero Universitaria Modena
Modena, Italy
San Gerardo Hospital
Monza, Italy
Ospedale Santa Maria delle Croci
Ravenna, Italy
National Cancer Center Hospital East
Chiba, Japan
Niigata Cancer Center
Niigata, Japan
Osaka City General Hospital
Osaka, Japan
Osaka International Cancer Institute
Osaka, Japan
Shizuoka Cancer Center
Shizuoka, Japan
National Cancer Center Hospital
Tokyo, Japan
The Cancer Institute Hospital of Japanese Foundation for Cancer Research
Tokyo, Japan
The Netherlands Cancer Institute (NKI)
Amsterdam, Netherlands
Leiden University Medical Center
Leiden, Netherlands
Singapore Clinical Research Institute
Singapore, Singapore
National Cancer Centre Singapore
Singapore, Singapore
National Cancer Center
Goyang-si, South Korea
Seoul National University Bundang Hospital (SNUBH)
Gyeonggi-do, South Korea
Gachon University Gil Medical Center
Incheon, South Korea
Showing 40 of 64 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.